---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009236"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:17:58.171448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023

## Summary
- Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.
- Net loss $35.7M vs $28.3M in 2021; R&D expenses $22.5M (+31% YoY).
- TPST-1120 Phase 1 showed 30% ORR at highest doses in checkpoint-inhibitor non-responsive patients.
- Randomized Phase 1b/2 study in first-line HCC fully enrolled; initial data expected H1 2023.
- TPST-1495 Phase 1 dose escalation ongoing; initial data expected by mid-2023.

## SEC filing metadata
- accession: 0000950170-23-009236
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/tpst-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009236
- JSON: https://secwatch.observer/filing/0000950170-23-009236.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009236.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $35.7 million, EPS $3.09.
  - Period: the year ended December 31, 2022
  - Net income: $35.7 million
  - EPS: $3.09
  - Result: reported results
  source text: Net loss and net loss per share for the year were $35.7 million and $3.09, respectively, compared to $28.3 million and $7.47, respectively, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.